Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences initiated a Phase 2 clinical study assessing crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). The 24-week, open-label study aims to evaluate safety and tolerability in 20 participants, potentially supporting a supplemental New Drug Application to expand the current indication for CRENESSITY.
Key figures
- Drug Name
- crinecerfont
- Phase Of Trial
- Phase 2
- Duration
- 24-week
- Participants
- 20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.